NO319829B1 - Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet - Google Patents
Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet Download PDFInfo
- Publication number
- NO319829B1 NO319829B1 NO19975492A NO975492A NO319829B1 NO 319829 B1 NO319829 B1 NO 319829B1 NO 19975492 A NO19975492 A NO 19975492A NO 975492 A NO975492 A NO 975492A NO 319829 B1 NO319829 B1 NO 319829B1
- Authority
- NO
- Norway
- Prior art keywords
- cortisol
- dexamethasone
- dose
- agonist
- use according
- Prior art date
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 16
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 16
- 238000003745 diagnosis Methods 0.000 title claims abstract description 4
- 208000030159 metabolic disease Diseases 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 122
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 61
- 239000000556 agonist Substances 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 10
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 8
- 206010020772 Hypertension Diseases 0.000 claims abstract description 7
- 210000004369 blood Anatomy 0.000 claims abstract description 6
- 239000008280 blood Substances 0.000 claims abstract description 6
- 229960003957 dexamethasone Drugs 0.000 claims description 24
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 10
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 9
- 206010065941 Central obesity Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 6
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 239000002395 mineralocorticoid Substances 0.000 claims description 4
- 150000001886 cortisols Chemical class 0.000 claims description 3
- 230000002567 autonomic effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 abstract description 2
- 239000003925 fat Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100021752 Corticoliberin Human genes 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229940098777 Corticosteroid agonist Drugs 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical class O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
- Combined Controls Of Internal Combustion Engines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9501991A SE505391C2 (sv) | 1995-05-30 | 1995-05-30 | Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet |
| PCT/SE1996/000708 WO1996038179A1 (en) | 1995-05-30 | 1996-05-30 | Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO975492D0 NO975492D0 (no) | 1997-11-28 |
| NO975492L NO975492L (no) | 1998-01-27 |
| NO319829B1 true NO319829B1 (no) | 2005-09-19 |
Family
ID=20398470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19975492A NO319829B1 (no) | 1995-05-30 | 1997-11-28 | Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6410339B1 (sv) |
| EP (1) | EP0835138B1 (sv) |
| JP (1) | JPH11505850A (sv) |
| CN (1) | CN1078479C (sv) |
| AT (1) | ATE235258T1 (sv) |
| AU (1) | AU716671B2 (sv) |
| BR (1) | BR9608683A (sv) |
| CA (1) | CA2222215A1 (sv) |
| DE (1) | DE69626982T2 (sv) |
| DK (1) | DK0835138T3 (sv) |
| ES (1) | ES2189872T3 (sv) |
| NO (1) | NO319829B1 (sv) |
| PT (1) | PT835138E (sv) |
| RU (1) | RU2171471C2 (sv) |
| SE (1) | SE505391C2 (sv) |
| WO (1) | WO1996038179A1 (sv) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217505B2 (en) * | 1998-02-26 | 2007-05-15 | Cortendo Ab | Method for determining whether condition is symptom of metabolic syndrome |
| SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US20040220190A1 (en) * | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
| US20050215558A1 (en) * | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
| US8137993B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
| US8137994B2 (en) * | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
| US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
| DE102004034640A1 (de) | 2004-07-16 | 2006-02-16 | Institut für Molekular- und Systemmedizin | Verfahren zur systemischen Biokorrektur eines Organismus |
| US20090117660A1 (en) * | 2005-04-30 | 2009-05-07 | Oakville Hong Kong Co., Limited | Devices and methods for sample collection and analysis |
| RU2520080C2 (ru) * | 2006-10-06 | 2014-06-20 | Нестек С.А. | Композиции и мультипараметричекие способы анализа для измерения биологических медиаторов физиологического здоровья |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| RU2444298C1 (ru) * | 2010-07-15 | 2012-03-10 | Учреждение Российской академии медицинских наук Научный центр клинической и экспериментальной медицины Сибирского отделения РАМН (НЦКЭМ СО РАМН) | Способ диагностики метаболического синдрома |
| CN105973881A (zh) * | 2016-04-27 | 2016-09-28 | 樊福好 | 一种检测机体活度的溶液及检测方法 |
-
1995
- 1995-05-30 SE SE9501991A patent/SE505391C2/sv not_active IP Right Cessation
-
1996
- 1996-05-30 AT AT96916423T patent/ATE235258T1/de not_active IP Right Cessation
- 1996-05-30 WO PCT/SE1996/000708 patent/WO1996038179A1/en active IP Right Grant
- 1996-05-30 AU AU59173/96A patent/AU716671B2/en not_active Ceased
- 1996-05-30 US US08/952,638 patent/US6410339B1/en not_active Expired - Fee Related
- 1996-05-30 EP EP96916423A patent/EP0835138B1/en not_active Expired - Lifetime
- 1996-05-30 DK DK96916423T patent/DK0835138T3/da active
- 1996-05-30 CN CN96194229A patent/CN1078479C/zh not_active Expired - Fee Related
- 1996-05-30 ES ES96916423T patent/ES2189872T3/es not_active Expired - Lifetime
- 1996-05-30 BR BR9608683-1A patent/BR9608683A/pt not_active Application Discontinuation
- 1996-05-30 JP JP8536000A patent/JPH11505850A/ja not_active Ceased
- 1996-05-30 CA CA002222215A patent/CA2222215A1/en not_active Abandoned
- 1996-05-30 DE DE69626982T patent/DE69626982T2/de not_active Expired - Fee Related
- 1996-05-30 PT PT96916423T patent/PT835138E/pt unknown
- 1996-05-30 RU RU97121292/14A patent/RU2171471C2/ru not_active IP Right Cessation
-
1997
- 1997-11-28 NO NO19975492A patent/NO319829B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69626982T2 (de) | 2004-03-04 |
| NO975492D0 (no) | 1997-11-28 |
| RU2171471C2 (ru) | 2001-07-27 |
| DE69626982D1 (de) | 2003-04-30 |
| EP0835138A1 (en) | 1998-04-15 |
| WO1996038179A1 (en) | 1996-12-05 |
| EP0835138B1 (en) | 2003-03-26 |
| AU716671B2 (en) | 2000-03-02 |
| ES2189872T3 (es) | 2003-07-16 |
| AU5917396A (en) | 1996-12-18 |
| CN1078479C (zh) | 2002-01-30 |
| ATE235258T1 (de) | 2003-04-15 |
| SE505391C2 (sv) | 1997-08-18 |
| CA2222215A1 (en) | 1996-12-05 |
| CN1185743A (zh) | 1998-06-24 |
| PT835138E (pt) | 2003-08-29 |
| JPH11505850A (ja) | 1999-05-25 |
| NO975492L (no) | 1998-01-27 |
| MX9709234A (es) | 1998-10-31 |
| US6410339B1 (en) | 2002-06-25 |
| SE9501991L (sv) | 1996-12-01 |
| DK0835138T3 (da) | 2003-07-21 |
| BR9608683A (pt) | 1999-12-07 |
| SE9501991D0 (sv) | 1995-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS) | |
| NO319829B1 (no) | Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet | |
| Ferron et al. | Serum leptin concentrations in patients with anorexia nervosa, bulimia nervosa and non‐specific eating disorders correlate with the body mass index but are independent of the respective disease | |
| Hofmann et al. | Inhibin-B: the physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening | |
| Goland et al. | Elevated levels of umbilical cord plasma corticotropin-releasing hormone in growth-retarded fetuses | |
| Houdeau et al. | Sex steroid regulation of macrophage migration inhibitory factor in normal and inflamed colon in the female rat | |
| Stolk et al. | Gender differences in the associations between cortisol and insulin in healthy subjects | |
| Nieman et al. | The ovine corticotropin-releasing hormone (CRH) stimulation test is superior to the human CRH stimulation test for the diagnosis of Cushing's disease | |
| Fang et al. | Activiated galanin receptor 2 attenuates insulin resistance in skeletal muscle of obese mice | |
| Grulet et al. | Study of the rate of early glucose disappearance following insulin injection: insulin sensitivity index | |
| Armanini et al. | Alzheimer’s disease: pathophysiological implications of measurement of plasma cortisol, plasma dehydroepiandrosterone sulfate, and lymphocytic corticosteroid receptors | |
| Wodarz et al. | Normal lymphocyte responsiveness to lectins but impaired sensitivity to in vitro glucocorticoids in major depression | |
| Cleare et al. | Abnormal 5-HT1D receptor function in major depression: a neuropharmacological challenge study using sumatriptan | |
| Ferrier et al. | Gonadotrophin secretion abnormalities in chronic schizophrenia | |
| Franik et al. | The association between 24-hour ambulatory blood pressure measurement and selected biochemical and anthropometric parameters in women with polycystic ovary syndrome. | |
| Sumino et al. | Effects of hormone replacement therapy on office and ambulatory blood pressure in Japanese hypertensive postmenopausal women | |
| US7217505B2 (en) | Method for determining whether condition is symptom of metabolic syndrome | |
| MXPA97009234A (en) | Preparation for the diagnosis of the metabolic syndrome and diseases that include the sindr | |
| JP4044842B2 (ja) | 肥満を処置し得る薬剤のスクリーニング法 | |
| Khattak et al. | Comparison of Estradiol levels in Polycystic Ovary Syndrome and non-Polycystic Ovary Syndrome Infertile Patients | |
| Meijin et al. | A3081 VDR agonist prevents diabetic endothelial dysfunction through inhibition of prolyl isomerase-1 mediated mitochondrial oxidative stress and inflammation | |
| Hasan et al. | The Effect of Body Weight Gain with or Without Diabetes Type 2 on the Levels of Noradrenalin and Some Neurotrophins | |
| He et al. | Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid‐induced myopathy | |
| Shoaib et al. | Estemation of Serum Gonadotropin Hromones and Insulin levels among Stein-Leventhal syndrome Patients | |
| Abd Alkhalik et al. | Association of soluble E-selectin and morning blood pressure surge in patients with essential hypertension |